# Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

> **NCT03298984** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Alvocidib
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin

## Key facts

- **NCT ID:** NCT03298984
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-25
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298984, "Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03298984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*